Sarah Cannon Research Institute (SCRI) - Texas Oncology-Central South

Austin, Texas 78731

1 studies enrolling now · 1 studies all time

What they study most

Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) — Recruiting now